Following the release of its 2015 fourth quarter earnings report, Deerfield based Baxter International shares are now up 2.95%, with pre-market trading prices at $38.38.
The reported earnings of 37¢ per diluted share successfully beat analyst expectations, which were set at 32¢ per share before the opening of Tuesday's market. Revenue for the quarter was $2.6bn, exceeding the $2.54bn predicted by analysts.
Back in June, Baxter International announced its spinoff from Baxalta (BXLT), a biopharmaceutical firm. Now Baxter, which produces treatments for hemophilia, kidney disease, and immune disorders amongst other medical conditions, is looking forward to what the future holds.
On the morning of February 2, Chairman and CEO José Almeida explained the findings when it comes to the introductory expansion programs of the post-margins, and noted that there is a clear positive impact on the accomplishments of our fourth quarter.
TheStreet Ratings Team has evaluated the company's stock independently, granting Baxter a “Buy” rating with a score of B, citing that the company's strengths lie in its increasing profit margins, return on equity, and consistently performing stock prices.
Explaining the data to employees in the company newsletter could help them feel accomplished over their efforts and motivated. A newsletter printing service can do it clearly and use positive language, while also making sure that the documentation comes across as professional.
